Article Information
History
- August 7, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Xiao Li1,*,
- Lander Willem1,
- Caroline Klint Johannesen2,
- Arantxa Urchueguía-Fornes3,4,
- Toni Lehtonen5,
- Richard Osei-Yeboah6,
- Heini Salo5,
- Alejandro Orrico Sánchez3,4,7,
- Javier Díez Domingo3,4,7,
- Mark Jit8,
- PROMISE investigators,
- Joke Bilcke1,
- Harish Nair6 and
- Philippe Beutels1
- 1Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID), University of Antwerp, Belgium
- 2Department of Virology and Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen, Denmark
- 3Vaccine Research Department, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Valencia, Spain
- 4CIBER de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Valencia, Spain
- 5Finnish Institute for Health and Welfare, Helsinki, Finland
- 6Centre for Global Health, The University of Edinburgh, Edinburgh, United Kingdom
- 7Catholic University of Valencia, Valencia, Spain
- 8Department of Infectious Disease Epidemiology & Dynamics, London School of Hygiene & Tropical Medicine
- ↵*Corresponding authors Xiao Li Address: Centre for Health Economics Research & Modelling Infectious Diseases, Vaccine & Infectious Disease Institute, Campus Drie Eiken (D.R.212), Universiteitsplein 1 University of Antwerp, Belgium Email: xiao.li{at}uantwerpen.be
Posted August 07, 2024.
Influential drivers of the cost-effectiveness of respiratory syncytial virus vaccination in European older adults: A multi-country analysis
